Erasca Inc., a clinical-stage precision oncology company, reported financial results for the first quarter of 2025. The company's net loss for the quarter ended March 31, 2025, was $31.0 million, compared to a net loss of $35.0 million for the same period in 2024. The reduction in net loss was primarily attributed to a decrease in both Research and Development (R&D) expenses and General and Administrative (G&A) expenses. R&D expenses decreased to $26.0 million from $28.6 million, driven by reductions in personnel costs and clinical trial expenses. G&A expenses were reduced to $9.7 million from $10.3 million, primarily due to decreased legal fees and insurance costs. Erasca also highlighted its robust balance sheet with cash, cash equivalents, and marketable securities totaling $411 million as of March 31, 2025, and extended cash runway guidance to the second half of 2028. The company is advancing its RAS-targeting franchise, with initial Phase 1 monotherapy data for its product candidates ERAS-0015 and ERAS-4001 expected in 2026. Erasca's strategic focus on these candidates is aimed at addressing unmet medical needs in cancers such as colorectal, pancreatic, and non-small cell lung cancers.